IDEAYA Biosciences 的收益预期不及预期，但股价上涨，维持“适度买入”评级。 IDEAYA Biosciences misses earnings estimates but sees stock rise, keeping a "Moderate Buy" rating.

IDEAYA生物科学研究所报告,季度每股损失1.49美元,缺少分析员的估计数82美元,尽管其700万美元的收入达到了预期。 IDEAYA Biosciences reported a quarterly loss of $1.49 per share, missing analysts' estimates by $0.82, though its revenue of $7 million met expectations. 尽管收入不足,但股票上涨了0.24美元,分析师维持了“机动购买”评级,目标价格为53.58美元。 Despite the earnings miss, the stock rose by $0.24, and analysts maintain a "Moderate Buy" rating with a target price of $53.58. 该公司以癌症精密医学为重点,从多个分析家那里获得了购买评级。 The company, focused on precision medicine for cancer, has received buy ratings from multiple analysts.